Wednesday, March 31, 2021

The AstraZeneca Vaccine and the Proof That We Are Part of an Unprecedented Medical Experiment

Updated April 27, 2021


Since the whole COVID-19 narrative took over the world, I have been suspicious that we are all part of a massive and unprecedented social and, more recently, medical experiment.  Let's look at some proof from Global News and Canadian Broadcasting Corporation in Canada.  Keep in mind that all recommendations for vaccines in Canada are sourced from Canada's National Advisory Committee on Immunization (NACI).  In this posting, I will be supplying you with both the original NACI recommendations as well as the media coverage of the reports which is what most Canadians will see or read.

  

Let's start with the Recommendations on the use of COVID-19 vaccines from NACI dated March 1, 2021 and its recommendation for the use of the AstraZeneca COVID-19 vaccine:

 

This is how Global News covered the NACI report:

 

Now, let's move forward two weeks.  Here is what NACI had to say about the AstraZeneca vaccine in its statement dated March 16, 2021:

 

 

This is how the federal government-funded Canadian Broadcasting Corporation covered the NACI report:

 

Now, let's move forward another two weeks.  Here's what NACI had to say about the AstraZeneca vaccine on March 29, 2021:

 

 

Lastly, here is what NACI has to say about the AstraZeneca vaccine on April 23, 2021 after noting that the vaccine is authorized for use in Canada for those aged 18 and older:


Here is a detailed quote from the March 29th report showing how little medical experts and public health officers know about the serious side effects of the AstraZeneca vaccine with all bolds being mine:

  

"Rare cases of serious blood clots, including cerebral venous sinus thrombosis, associated with thrombocytopenia have been recently reported in Europe following post-licensure use of AstraZeneca COVID-19 vaccine. This entity is associated with the development of antibodies that "activate" platelets, which stimulate the formation of clots and result in thrombocytopenia. The mechanism of action is similar to heparin-induced thrombocytopenia (HIT). The exact mechanism by which the AstraZeneca vaccine triggers VIPIT is still under investigation. At this time, no other risk factors have consistently been identified in patients who develop VIPIT. This adverse event has not been identified following receipt of mRNA COVID-19 vaccines to date.

 

The rate of this adverse event is still to be confirmed. Based on information from the European Medicines Agency on March 18, 2021 it was originally estimated at approximately 1 per 1,000,000 people vaccinated with the AstraZeneca vaccine, however a higher rate of 1 per 100,000 was reported by the Paul-Ehrlich Institut in Germany.

 

Following population-based analyses of VIPIT assessing risk of COVID-19 disease by age, and considering that alternate products are available (i.e., mRNA vaccines), from what is known at this time, there is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccine to adults under 55 years of age given that the potential risks associated with VIPIT, particularly at the lower estimated rates. As a precautionary measure, while Health Canada carries out an updated benefit/risk analysis based on emerging data, NACI recommends that the vaccine not be offered to adults under the age of 55. Adults 55 years of age and older may still be offered the AstraZeneca vaccine with informed consent, given the increased risk of hospitalization and death due to COVID-19 disease in this population."

  

This is how the Canadian Broadcasting Corporation covered the NACI report:

 

Can you blame people for being "vaccine hesitant"? 


I understand that, as time passes, more adverse event data from the COVID-19 vaccines will become evident, however, the fact that these vaccines were rushed to market without completing phase 3 and phase 4 trials means that anyone being injected with one of the current crop of COVID-19 is taking a significantly higher risk of both non-severe and severe adverse events because the adverse events were not fully understood.  The experience of Canadians is proof positive that we are the subjects of a massive and unprecedented medical experiment brought to us by Big Pharma, our governments and our public health officials and that we are not being properly informed of the risks until after they become apparent.


Addendum dated April 27, 2021:


Here's a quote from the news item:


"Quebec Health Minister Christian Dubé said the province has vaccinated about 400,000 people with the AstraZeneca shot.

 

"It's a calculated risk, but evidently when we think of this woman, her family, her close ones... it's hard," Quebec Premier François Legault said of the patient, a 54-year-old woman."


I'm sure that is cold comfort to the unfortunate woman's family.


Tuesday, March 30, 2021

America's Megadrought and its Potential Impact on American Consumers

While we are distracted with the fear porn associated with the COVID-19 pandemic, a situation of great concern to the producers of our food is unfolding with very little meaningful recognition by the mainstream media, particularly given its seriousness.

  

Here is a recent news item from Fox6 in Milwaukee:

 


Let's look at the actual data from the United States Drought Monitor for the western United States:

 

 

Here is a table showing the data behind the map:

 


In mid-March 2021, 20.61 percent of the western United States was considered to be in an exceptional drought situation, down from 22.16 percent at the end of December 2020 but up from 0 percent in March 2020.  In total, 39.49 percent of the western United States is considered to be in an extreme or exceptional drought, down from 46.63 percent just prior to Christmas 2020 but, again up substantially from 0 percent in March 2020.


Here is the latest drought summary for the western United States with my bolds:

 

"A slight expansion of severe drought (D2) was made to northeast Montana, based on 90-day SPI (standardized precipitation index) and soil moisture below the 10th percentile. These low soil moisture conditions are related to the lack of snowfall this winter. In contrast to the northern high Plains, snow water content is running close to average for late March and led to the elimination of abnormal dryness (D0) across south-central Montana. Since parts of western Arizona and southeast California have received little to no precipitation during the past two month, D3 (extreme) and D4 (exceptional) drought were slightly increased. This expansion of D3-D4 was supported by 9-month SPI values which covers the failed 2020 monsoon and this past winter. An expansion of D2 (severe) and extreme (D3) drought across parts of southern California was based on large water year to date precipitation deficits and 6-month SPI values. No other changes were made at this time to the remainder of California as 6 to 12 month SPIs generally support the current depiction and snow water content is running near two-thirds of average for the Sierra Nevada Mountains. During subsequent weeks, the drought depiction will be reassessed across California. Although much of the precipitation this past week fell along the coast or over the Cascades, a reassessment of longer term SPIs dating back 6 to 12 months supported removal of the D2 (severe) drought in southwest Oregon. Due in part to recent high-elevation snow and rainfall during the past two weeks, a slight decrease in D3 (extreme) and D4 (exceptional) drought was made to northern and northeast New Mexico. However, widespread D4 persists across southeast New Mexico where dust storms have been quite frequent this month and soil moisture remains in the lowest one percentile."

  

Let's look at the drought situation for the entire continental United States.  Here is a map showing the drought situation for March 24, 2020:

 

 

Here is what the drought situation looked like by the beginning of August 2020:

 


Here is what the drought situation looked like at the end of December 2020:



Lastly, here is what the drought situation looks like now:

 

 

Given that, historically speaking, drought conditions in the continental United States tend to be very low during the early part of the year, the fact that an extreme drought is currently plaguing the west is of great concern for food producers of all types and for consumers and, given the current stresses in the world's supply chains, we may well find that significant food price inflation will result in even greater financial strain on American farmers and for American and Canadian consumers.



Monday, March 29, 2021

Moderna and mRNA Vaccine Research

While Moderna continues the human-wide, government-promoted and mandated Phase 3 trials of its unprecedented mRNA-1273 COVID-19 vaccine, the company appears to be putting significant effort into advancing its mRNA-based vaccine research inventory.  

 

Here is how Moderna defines mRNA (messenger RNA):

 

"Messenger RNA, or mRNA, plays a fundamental role in human biology, transferring the instructions stored in DNA to make the proteins required in every living cell. mRNA provides instructions to cells to make protein. Moderna’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. We are also working to advance the development mRNA therapeutics that restore the activity of missing enzymes responsible for various rare diseases, such as methylmalonic acidemia (MMA) and propionic acidemia (PA)."

  

Messenger RNA vaccines are a completely new line of vaccines.  Here is some background information on mRNA vaccines from Harvard Health Blog

 

"The main goal of a vaccine for a particular infectious agent, such as the virus that causes COVID-19, is to teach the immune system what that virus looks like. Once educated, the immune system will vigorously attack the actual virus, if it ever enters the body.

 

Viruses contain a core of genes made of DNA or RNA wrapped in a coat of proteins. To make the coat of protein, the DNA or RNA genes of the virus make messenger RNA (mRNA); the mRNA then makes the proteins. An mRNA of a specific structure makes a protein of a specific structure.

 

About 30 years ago, a handful of scientists began exploring whether vaccines could be made more simply. What if you knew the exact structure of the mRNA that made the critical piece of a virus’s protein coat, such as the spike protein of the COVID-19 virus?

 

It is relatively easy to make that mRNA in the laboratory, in large amounts. What if you injected that mRNA into someone, and the mRNA then traveled through the bloodstream to be gobbled up by immune system cells, and then those cells started to make the spike protein? Would that educate the immune system?

 

While the concept seems simple, it required decades of work for mRNA vaccines to overcome a series of hurdles. First, scientists learned how to modify mRNA so that it did not produce violent immune system reactions. Second, they learned how to encourage immune system cells to gobble up the mRNA as it passed by in the blood. Third, they learned how to coax those cells to make large amounts of the critical piece of protein. Finally, they learned how to enclose the mRNA inside microscopically small capsules to protect it from being destroyed by chemicals in our blood.

 

Along the way, they also learned that, compared to traditional vaccines, mRNA vaccines can actually generate a stronger type of immunity: they stimulate the immune system to make antibodies and immune system killer cells — a double strike at the virus."

 

Here is a diagram from Moderna showing how its mRNA vaccines work:

 

Here is a video from Moderna featuring the company's president Dr. Stephen Hoge and its Chief Scientific Officer Paolo Martini on how Moderna is delivering on its mRNA therapies:

 


Now, let's look at Moderna's current research on mRNA vaccines, most of which are still in Phase 1 or 2 clinical study with the notable exception of the COVID-19 mRNA-1273 vaccine:  

 

Who is backing this research?  Here's the answer:

 

 

Shocking, isn't it?   In "Gatesworld" there's nothing that can't be solved with a heavy dose of technology and a hefty influx of a seemingly endless bundle of cash.

 

Let's close with this information from the Centers for Disease Control and Prevention on mRNA vaccines:

 

"There are currently no licensed mRNA vaccines in the United States. However, researchers have been studying them for decades.

 

Early stage clinical trials using mRNA vaccines have been carried out for influenza, Zika, rabies, and cytomegalovirus (CMV). Challenges encountered in these early trials included the instability of free RNA in the body, unintended inflammatory outcomes, and modest immune responses. Recent technological advancements in RNA biology and chemistry, as well as delivery systems, have mitigated these challenges and improved their stability, safety, and effectiveness.

 

Beyond vaccines, numerous preclinical and clinical studies have used mRNA to encode cancer antigens to stimulate immune responses targeted at clearing or reducing malignant tumors."

 

Given that mRNA vaccines are unprecedented and that Moderna's mRNA-1273 vaccine is not scheduled to complete its phase 3 clinical trial until October 27, 2022 as shown here:

 

...we are all unwitting animal test subjects in the very early days of a new unproven technology.

 

Friday, March 26, 2021

COVID-19 Vaccines - How Big Pharma is Using Our Children as Guinea Pigs

We all know that vaccines must/should be thoroughly tested before they are unleashed on the public, using a large sample with varying age profiles and health conditions, however, recent developments in the COVID-19 vaccine race are concerning.

  

Here is the Sponsor Briefing Document that was released by Janssen Biotech Inc, a subsidiary of the Johnson & Johnson Company in support of its COVID-19 vaccine, Ad26.COV2.S for its Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting with the FDA on February 26, 2021:

 

Janssen Biotech was seeking Emergency Use Authorization for the use of its vaccine for adults 18 years of age and older.  

 

The Phase 3 study COV3001 is ongoing with a multicenter, randomized, double-blind palacebo-controlled study to assess the efficacy, safety and immunogenicity of a single dose of AD26.COV2.S vaccine with 43,783 participants 18 years and older in the United States, South Africa, Brazil, Chile, Argentina, Columbia, Peru and Mexico as shown on this table:

 

...and this table:


 

To this point, the Johnson & Johnson vaccine has been tested on a total of 21,895 individuals along with 21,888 individuals who received the placebo as shown on this table which shows the overall results of the study:

 

You can't be blamed for not wading through the entire 118 page document, however, there is one key insight that can be found on page 34 which outlines the company's planned clinical studies for its COVID-19 vaccine:

 

 

Note that Study COV3006 will involve children from birth to age 18 and Study COV2004 will involve pregnant women and their infant children. 

 

Now that we have that background, let's look at a recent announcement from Moderna, purveyor of the mRNA-1273 COVID-19 vaccine:

 

 

Here is a quote from the news release:

 

"Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

 

“We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada and we thank NIAID and BARDA for their collaboration,” said Stéphane Bancel, Chief Executive Officer of Moderna. “It is humbling to know that 53 million doses have been administered to people in the U.S. We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.”

 

This Phase 2/3 two-part, open label, dose-escalation, age de-escalation (Part 1) and randomized, observer-blind, placebo-controlled expansion study (Part 2) will evaluate the safety, tolerability, reactogenicity and effectiveness of two doses of mRNA-1273 given 28 days apart. The Company intends to enroll approximately 6,750 pediatric participants in the U.S. and Canada ages 6 months to less than 12 years.

 

In Part 1, each participant ages two years to less than 12 years may receive one of two dose levels (50 μg or 100 μg). Also in Part 1, each participant ages six months to less than 2 years may receive one of three dose levels (25 μg, 50 μg and 100 μg). An interim analysis will be conducted to determine which dose will be used in Part 2, the placebo-controlled expansion portion of the study. Participants will be followed through 12 months after the second vaccination. Vaccine effectiveness will either be inferred through achieving a correlate of protection, if established, or through immunobridging to the young adult (ages 18-25) population. Evaluation of vaccine safety and reactogenicity is also a primary endpoint of the study. The ClinicalTrials.gov identifier is NCT04796896."

 

If you want to enrol your child, you can get more information on kidcovestudy.com:

 

Moderna claims that a vaccine that prevents the transmission of the SARS-CoV-2 virus in children  "would be a crucial public health tool to help curb the pandemic".  They neglect to mention that there is no research to show that the mRNA-1273 vaccine prevents transmission of the COVID-19 virus and that the mortality rate for children from the virus is negligible as shown in this table from the CDC:

 

 

...and here:


Given that no pharmaceutical researcher, scientist, physician or Big Pharma executive has any idea what the long-term ramifications of the unprecedented COVID-19 vaccines, particularly Moderna's mRNA vaccine, will be on the health of the human race, it is interesting to see that Big Pharma is urging parents to volunteer their children for an experiment, the results of which have the potential to negatively impact their health for the remainder of their lives.


Thursday, March 25, 2021

The Pandemic and Its Impact on American Workers

There is little doubt that the government response to the COVID-19 pandemic has had a massive impact on employment in the United States.  In the Federal Reserve's most recent iteration of its Monetary Policy Report, the Fed outlines the disparities in job losses during the pandemic.

  

Let's start with this graphic which shows the civilian unemployment rate:

 

During the early stages of the pandemic in March and April of 2020, payroll unemployment plunged by 22 million jobs as shown here:

 

... pushing the headline unemployment rate to 14.8 percent, the highest rate since the Great Depression nearly a century ago. 

 

We also must keep in mind that a substantial number of American workers were put on temporary layoff and should have been counted as unemployed but who were recorded as "employed but on unpaid absence".  If the Bureau of Labor Statistics had correctly classified these workers, the unemployment rate in April 2020 would have been 5 percentage points higher, hitting 19.8 percent.  This misclassification has abated over the remainder of 2020 and, according to the Fed, the real unemployment rate is now only 0.5 percentage points lower than it should be because of the misclassification.

 

Nonfarm payroll employment did rise to its current level of 119.796 million over the coming months, pushing the unemployment rate back down , however at 6.3 percent in January 2021, it is still nearly 3 percentage points higher than the 3.5 percent level prior to the pandemic recession.  As well, between November 2020 and January 2021, the monthly gains in payroll averaged just 29,000 per month with the unemployment rate only declining by 0.4 percent over the three months.  This is largely because of the government-mandated lockdowns associated with the so-called "second wave".

  

Here is a quote from the report:

 

"The damage to the labor market has been even more substantial than is indicated by the extent of unemployment alone. The labor force participation rate (LFPR)—the share of the population that is either working or actively looking for work—plunged in March and April, as many of those who lost their jobs were not seeking work and so were not counted among the unemployed. Despite recovering some over the summer, the LFPR remains nearly 2 percentage points below its pre-pandemic level."

 

Here is a graphic showing the impact of the pandemic recession on the labor force participation rate and the employment-to-population level:


The Fed believes that there are a number of factors that have worked together to keep the labor force participation rate at its lowest level since March 1976:

 

Here three of the reasons for the low labor force participation rate:


1.) a lack of job opportunities

 

2.) the effects of school closures and virtual learning on parents' ability to work

 

3.) a spate of early retirements triggered by the crisis


The pandemic recession has had a significantly worse impact on employment for non-white workers as shown on this graphic:

 

This is largely because job losses during 2020 fell disproportionately on lower-wage workers (i.e. Hispanics, African Americans and other minority groups) as shown on this graphic:

 

In January 2021, employment in the lowest paying jobs was still about 20 percent below its pre-pandemic recession level compared to about 10 percent or less for higher paying jobs.

 

Now, let's look at the disparities in job losses during the pandemic.  Workers in certain private-sector industries have experienced far worse employment opportunities thanks to the government-mandated response to the COVID-19 pandemic, in particular, the mandate for physical and social distancing.  Here is a table showing which industries have seen the significant changes in employment both during the initial phases of the pandemic in April 2020 and, to compare, in January 2021:

 

This graphic shows us that in February 2021, some sectors showed improvement on a month-over-month basis but some are still suffering:


Despite what happened in February 2021, over the past year, the massive job losses in leisure and hospitality should not be a surprise; this industry was most impacted by social and physical distancing measures including government-imposed limits on capacity and the fact that these workers, for the most part, cannot work from home.

  

One would like to think that as the pandemic wanes, the employment situation in the United States will improve.  This is not necessarily the case for some workers as shown in this quote from the Fed report:

 

"In January 2021, 2.2 percent of labor force participants (representing 34.6 percent of unemployed workers) reported being unemployed because of a permanent job loss, up from 1.3 percent of the labor force (8.8 percent of unemployed workers) in April 2020.  Research has shown that workers who return to their previous employers after a temporary layoff tend to earn wages similar to what they were making previously, whereas laid-off workers who do not return to their previous employer experience a longer-lasting decline in earnings."

 

As the pandemic wanes, while America's beleaguered workers will see signs of improvement in their job prospects, however, it appears that some of the jobs will be permanently lost, particularly in the leisure and hospitality industries and the retail sector thanks to the permanent closures of hundreds of thousands of restaurants and retail outlets.  There is little doubt that the post-pandemic employment picture in the United States will look far different than it did at the beginning of 2020.  Even those who are able to find a new job are likely to experience a lengthy decline in earnings.

 

Addendum

 

The United States is not in a unique situation when it comes to employment and the post-pandemic recession reality.  In a recent report from the Canadian Chamber of Commerce, 51.3 percent of all businesses do not know how long they will continue to be able to operate and 29.6 percent of businesses in accommodation and food services expect to reduce their number of employees as shown here:

 

1.) Only 38.4% of businesses expect they’ll be able to operate for 12 months or longer at current revenue levels.


2.) 51.3% of all business do not know how long they’ll be able to continue to operate at current revenue levels, with smaller businesses facing higher unknowns (52.2% for 1-4 employees; 50.9% for 5-19 employees; 49.3% for 20-99 employees; 44.2% for 100 or more employees).


3.) Nearly half (46.4%) of businesses did not know how long they could continue to operate at current levels before considering laying off staff.


4.) Close to one-third (29.6%) of businesses in accommodation and food services expect a reduction in their number of employees over the next three months.


5.) More small businesses are at their debt limit: 41.8% of businesses with 1-4 and 5-19 employees are unable to take on more debt; 29.0% for 20-99 employees; 17.1% for 100 or more employees.


Wednesday, March 24, 2021

The Evolution of the SARS-CoV-2 Virus

While public health officials and governments around the world are hard-selling us the COVID-19 variant fear porn in an effort to keep us under control, in fact, as you will see in this posting, the original SARS-CoV-2 virus has been evolving over the past year.


From the CDC website, here is a description of the three SARS-CoV-2 variants that have been detected in the United States and other nations around the world along with the date and location of first detection in the United States:

 

1.) The B.1.1.7 variant was first detected in the United Kingdom in December 2020 and likely first emerged there in September 2020. Colorado reported the first U.S. case of the B.1.1.7 variant in late December 2020. Since then, B.1.1.7 has been detected in at least 42 jurisdictions. Preliminary data from the United Kingdom suggest that the B.1.1.7 variant spreads more easily and may cause more severe disease than previous variants of SARS-CoV-2.4 

 

2.) The B.1.351 variant was first detected in the Republic of South Africa in December 2020, and likely first emerged there in October 2020. At least 35 countries, including the United States, have detected COVID-19 cases of infection with the B.1.351 variant. The first detected U.S. cases of infection with the B.1.351 variant occurred in South Carolina and Maryland in late January 2021 and have now been documented in at least 10 jurisdictions. Some data suggest that people previously infected with SARS-CoV-2 may have less immune protection if they are re-infected with the B.1.351 variant.

 

3.) The P.1 variant was first detected in Japan in travelers from Brazil in January 2021. Minnesota reported the first U.S. case of infection with the P.1 variant in January 2021 and P.1 has now been identified in Oklahoma, Maryland, and Florida.

 

So far, this many cases of each variant have been discovered in the United States:

 

Now, let's look at additional information about the evolution of the SARS-CoV-2 virus. Let's start by looking at the concept of phylogeny.  According to an article on ThoughtCo, phylogeny attempts to trace the evolutionary history of all life on earth.  More specifically, phylogeny looks at the relationship among organisms as indicated by the use of genetic comparisons.  A phylogeny is represented in a diagram known as a phylogenetic tree with the branches of the tree representing ancestral or descendent lineages, much like a human family tree.  Relatedness in a phylogenic tree is determined by descent from a common ancestor.  Here is a link to a very basic description of phylogeny and how it is used to classify organisms.

  

With that background, let's look at the phylogeny of the SARS-CoV-2 virus as reported on the Nextstrain website.  Here is a graphic showing the very complex phylogeny of the SARS-CoV-2 virus:



The horizontal lines on this graphic show the genetic relationships between each of the variants and depict how closely related the viruses are to each other with the longer horizontal lines meaning that there are more differences between them.  As you can see, since SARS-CoV-2 first appeared in December 2019, the virus has undergone significant evolution.

  

Here is a map showing the geographical spread of the evolution of the SARS-CoV-2 virus:

 


Let's look at a quote from the Nextstrain website regarding these graphics:

 

"This phylogeny shows evolutionary relationships of SARS-CoV-2 viruses from the ongoing COVID-19 pandemic. Although the genetic relationships among sampled viruses are quite clear, there is considerable uncertainty surrounding estimates of specific transmission dates and in reconstruction of geographic spread. Please be aware that specific inferred geographic transmission patterns and temporal estimates are only a hypothesis.

 

There are hundreds of thousands of complete SARS-CoV-2 genomes available and this number increases every day. This visualization can only handle ~3000 genomes in a single view for performance and legibility reasons. Because of this we subsample available genome data for these analysis views. Our primary global analysis subsamples to ~600 genomes per continental region with ~400 from the previous 4 months and ~200 from before this. This results in a more equitable global sequence distribution, but hides samples available from regions that are doing lots of sequencing. To mitigate against this, we've set up separate analyses to focus on particular regions. They are available on the "Dataset" dropdown on the left or by clicking on the following links: Africa, Asia, Europe, North America, Oceania and South America.

 

Site numbering and genome structure uses Wuhan-Hu-1/2019 as reference. The phylogeny is rooted relative to early samples from Wuhan."

  

Let's close with a quote from an article by Erin Garcia de Jesus from Sciencenews.org:

 

"Viruses are always changing. When a virus infects a cell, it begins making copies of its genetic instructions. Most viruses don’t have the necessary tools to proofread each string of RNA for mistakes, so the process is error-prone and differences build up over time. 

 

Coronaviruses like SARS-CoV-2, on the other hand, do have a proofreading enzyme — a rarity for RNA viruses. But that doesn’t mean their genomes don’t have errors. Changes still accumulate, just more slowly than in other RNA viruses such as influenza. “Strains,” “variants” or “lineages” are all terms researchers might use to describe viruses that have identical or closely related strings of RNA. 

 

But for the general public, a word like “strain” is often interpreted to mean a whole new scourge. “I think the use of the term ‘strain’ does little more than cause panic,” says Jeremy Luban, a virologist at the University of Massachusetts Medical School in Worcester. “It doesn’t really get at what the important issues are.”

 

A mutation can affect a virus in a number of ways, but only certain kinds of mutations might make the virus more dangerous to people. Perhaps the change shields the virus from the immune system, or makes it resistant to treatments. Mutations could also alter how easily the virus spreads among people or cause shifts in disease severity. 

 

Luckily, such mutations are rare. Unfortunately, they can be hard to identify."


There have been preliminary studies on the new variants:


1.) P.1 variant - research here which states that "The recent emergence of variants with multiple shared mutations in spike raises concern about convergent evolution to a new phenotype, potentially associated with an increase in transmissibility or propensity for re-infection of individuals."


2.) Notes from a January 21, 2021 meeting of the U.K.'s influential Committee New and Emerging Respiratory Virus Threats Advisory Groups (NERVTAG) quoted modelling papers that have not yet been published.  Minutes of the meeting show this:



Studying viral mutations is a long and complicated process and is well beyond the intellectual capabilities of most of our elected leaders. In order to understand whether a viral mutation is dangerous to humans, animal or human studies are necessary and these studies take time.  Given the hasty response to the current variants suggests that governments are using the appearance of new strains of the SARS-CoV-2 virus to bolster their fear porn-based agendas when, in fact, viruses have mutated for millennia.